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Abstract
Background: The tissue-specific translation elongation factor eEF1A2 was recently shown to be
a potential oncogene that is overexpressed in ovarian cancer. Although there is no direct evidence
for an involvement of eEF1A2 in breast cancer, the genomic region to which EEF1A2 maps, 20q13,
is frequently amplified in breast tumours. We therefore sought to establish whether eEF1A2
expression might be upregulated in breast cancer.
Methods: eEF1A2 is highly similar (98%) to the near-ubiquitously expressed eEF1A1 (formerly
known as EF1-α) making analysis with commercial antibodies difficult. We have developed specific
anti-eEF1A2 antibodies and used them in immunohistochemical analyses of tumour samples. We
report the novel finding that although eEF1A2 is barely detectable in normal breast it is moderately
to strongly expressed in two-thirds of breast tumours. This overexpression is strongly associated
with estrogen receptor positivity.
Conclusion: eEF1A2 should be considered as a putative oncogene in breast cancer that may be a
useful diagnostic marker and therapeutic target for a high proportion of breast tumours. The
oncogenicity of eEF1A2 may be related to its role in protein synthesis or to its potential non-
canonical functions in cytoskeletal remodelling or apoptosis.
Background
Breast cancer is the most common cancer in females
worldwide; there are an estimated 1 million new cases per
year [1]. The identification of changes in gene expression
in breast tumours relative to normal surrounding tissue is
clearly of great importance in terms of prognostic indica-
tors and therapeutic targets.
The translation elongation factor eEF1A2 was first identi-
fied as a tissue-specific variant of eEF1A1 (formerly
known as EF-1α) in the early 1990s [2,3]. The two forms
of eEF1A are encoded by separate loci, but the resulting
proteins are 92% identical and 98% similar. Whereas
eEF1A1 is widely expressed, eEF1A2 is normally expressed
only in neurons and muscle [3-5]. The first specific
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evidence implicating eEF1A2 in tumourigenesis came in
2002 when Anand et al [6] showed that eEF1A2 was
expressed in 30% of ovarian tumours, but not in normal
ovary. The genomic region to which eEF1A2 maps, 20q13,
had been known for many years to be amplified in a high
proportion of ovarian and breast tumours [7]; [8], but the
EEF1A2 gene maps closer to the telomere than the region
previously implicated. Anand et al showed that 14/53
tumours had amplifications of the region surrounding
EEF1A2  [6]. In the same paper, forced expression of
eEF1A2 in cells was demonstrated to confer tumourigenic
properties on NIH3T3 cells, and to give rise to tumours in
xenografted nude mice. Although 20q13 amplification is
commonly observed in breast cancer, there has as yet been
no evidence for overexpression of eEF1A2 in breast
tumours. However, eEF1A1, the widely-expressed iso-
form, was recently shown to be upregulated in the infil-
trating edge of invasive breast tumours compared with the
tumour core by microarray analysis of laser microdis-
sected material, confirmed by immunohistochemistry [9].
In this analysis the antibody used was one that detects
both eEF1A1 and eEF1A2 with equal intensity, so it is con-
ceivable that eEF1A2 contributes to this pattern of
expression.
We have generated antibodies (Newbery et al, in prepara-
tion) that allow us to distinguish between the highly
related isoforms eEF1A1 (which is expressed in normal
breast) and eEF1A2 (which is thought to be expressed
only in muscle and neurons). Using these isoform-specific
antibodies, we show that eEF1A2 expression is barely
detectable in normal human breast tissue, but that the
gene is moderately to strongly expressed in 63 % of breast
tumours examined. Furthermore, there is a strong correla-
tion between eEF1A2 overexpression and estrogen recep-
tor (ER) positivity.
Methods
Quantitative Real-time Reverse Transcription-PCR (RT-
PCR)
Breast cancer samples were obtained in the Edinburgh
Breast Unit (Western General Hospital, Edinburgh) with
patients' informed consent and ethical committee
approval. Biopsies were snap frozen and stored in liquid
nitrogen until RNA extraction. Before RNA extraction the
frozen tissue was defrosted and stabilized in RNA-later-
ICE reagent (Ambion). Total RNA was extracted with RNe-
asy-mini columns (Qiagen).
Amount and purity of RNA were evaluated by spectropho-
tometry. RNA integrity was confirmed by agarose gel elec-
trophoresis. Total RNA was isolated from tumour and
normal tissue using Qiagen RNeasy kits (Qiagen). RNA
was treated with DNase using DNAfree kit (Ambion,
Cambridgeshire) and 1 µg was used for RT-PCR using Ret-
roscript kit (Ambion, Cambridgeshire, UK). TaqMan
Assay-on-Demand gene expression pre-designed primer
and probe sets from Applied Biosystems, Cheshire, UK
were used for EEF1A2 (Assay # Hs 00157325 ml) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
control; Hs 99999905 ml). In a 10 µl reaction volume per
well of a 394-well plate, 0.5 µl of primers, 5 µl of TaqMan
PCR Master Mix, no AmpErase UNG 10×, and 4.5 µl of
diluted cDNA were added (Applied Biosystems, Cheshire,
UK). Real-time RT-PCR and the quantification of RT-PCR
products were performed and the products analyzed using
an ABI Prism 7900HT Sequence Detection System, and
the appropriate software (SDS3.1) according to the man-
ufacturer's instructions (Applied Biosystems, Cheshire,
UK).
Western blots
Protein lysates from cell lines were prepared using previ-
ously published protocols [10]. Western blot analyses
were carried out using standard protocols. The blots were
incubated with primary anti-eEF1A2 rabbit antibody and
primary anti-eEF1A1 sheep antibody diluted 1:200 in
blocking solution, as well as primary anti-glyceraldehyde-
3-phosphate dehydrogenase polyclonal mouse antibody
(Chemicon International, Hampshire, UK) diluted
1:10000. Blots were then incubated in the appropriate
horse radish peroxidase conjugated secondary antibody
(Dako Cytomation, Cambridgeshire, UK) at 1:500. Detec-
tion was performed using enhanced chemiluminescence
detection kit (Amersham Biosciences, Buckinghamshire,
UK).
Immunohistochemistry
Specimens of normal and cancerous tumours were
obtained with informed consent and local ethical com-
mittee approval from patients undergoing surgical treat-
ment at the Royal Infirmary of Edinburgh and Western
General Hospital, Edinburgh. A breast tumour histoarray
(CB2) produced by SuperBioChips (AMS Biotechnology,
Oxfordshire, UK) was also used. Formalin fixed, paraffin
embedded sections of human normal tissue and tumour
tissue were deparaffinized with xylene, rehydrated, treated
with picric acid and microwaved in citric acid pH6. Slides
were blocked in a 1:5 dilution of sheep serum for 30 min-
utes at room temperature. Primary anti-eEF1A2 rabbit
antibodies were used at a concentration of 1:10 diluted in
PBS, for 40 minutes at room temperature and secondary
goat anti-rabbit IgG biotin conjugated antibody (Dako
Cytomation, Cambridgeshire, UK) was used at 1:200 at
room temperature for 30 minutes. Slides were incubated
with StreptABC complex/HRP (Dako Cytomation, Cam-
bridgeshire, UK) at room temperature for 30 minutes and
in diaminobenzidene (Sigma Fast DAB, Sigma, Dorset,
UK) for 2 minutes at room temperature. Finally slidesBMC Cancer 2005, 5:113 http://www.biomedcentral.com/1471-2407/5/113
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were counterstained in haematoxylin, dehydrated and
mounted in pertex.
Immunohistological scoring methods
The breast tumour sections and normal breast sections
(CB2, SuperBioChips, AMS Biotechnology, Oxfordshire,
UK) were scored as weak, moderate and strong staining
for eEF1A2. Weak staining was considered as background
since this level of staining is seen in normal tissue. Stro-
mal tissue was negative in all cases. Blind scoring was car-
ried out by two independent researchers. Two slides were
analysed, representing different levels within tumours,
and each of these was stained with a different antibody to
eEF1A2. Almost perfect correlation was seen between the
two slides.
Statistical methods
Fisher's exact test was used to test for associations between
negative and weak eEF1A2 expressing tumours or moder-
ately and strongly overexpressing tumours with ER posi-
tivity. For breast tumour Quantitative Real-time RT-PCR
data, a two-sample t-test allowing for difference in vari-
ance between the two samples was used to test the differ-
ence between the mean standardised quantity of RNA for
the ER-positive and ER-negative groups. P values that were
less than or equal to 0.05 were considered significant.
Results
Expression analysis in breast tumours
Since 20q13.3 amplification is commonly seen in breast
tumours as well as ovarian tumours, and because analysis
of the SAGE database at NCBI indicated that eEF1A2 was
more highly represented in breast tumours than in nor-
mal breast tissue (unpublished observations) we decided
to examine eEF1A2 expression in breast tumours at both
the RNA and protein level. Initially, we used Western blot-
ting with an anti-eEF1A2 antibody to examine expression
in a number of commonly-used cell lines. The anti-
eEF1A2 antibody was raised against a peptide that differs
significantly between eEF1A1 and eEF1A2 (Newbery et al,
in preparation); specificity was confirmed by lack of signal
from tissues taken from wasted mice which have a null
mutation of eEF1A2 [5]. The majority of transformed cell
lines showed high levels of expression of eEF1A2 (Figure
1); in addition, it has previously been shown that NIH3T3
cells do not express eEF1A2 except when they become
confluent [2,6]. We therefore chose not to place any
emphasis on the analysis of breast cancer cell lines as
opposed to primary tumour samples since eEF1A2 expres-
sion seems to be a common property of transformed cells,
rather than being specific for a tumour type. Instead, we
carried out real-time quantitative RT-PCR of RNA samples
from breast tumours. The results obtained are shown in
Figure 2A. It can be seen that whereas extremely low levels
of expression are detected in RNA samples from normal
breast and from a benign breast tumour, most malignant
tumour samples showed moderate to high (up to 30-fold
higher than normal breast) expression levels. On average,
the estrogen receptor (ER)-negative tumours showed only
1.2 times higher expression than the normal sample
whereas ER-positive tumours had 8.4 times higher expres-
sion (Figure 2B). The difference in eEF1A2 expression lev-
els between the estrogen receptor negative tumours and
estrogen receptor positive tumours is 7.2 units (P =
0.0087, t-test, 95% confidence interval 2.0 to 12.4 units).
No protein extracts were available from these tumours for
Western blot analysis so we then examined expression of
eEF1A2 by immunohistochemistry on a commercial tis-
sue array of normal and tumour breast samples using the
anti-peptide antibodies described above. The array con-
tained sections from 46 cases of cancer and 7 normal
breasts; the results obtained are shown in Figure 3. None
of the normal breast sections showed any more than faint
staining. No stromal staining was observed and tumour
staining within a sample was near-uniform. Of the
tumour samples, 5 showed strong expression of eEF1A2
(11%) and 22 showed moderate expression (48%). The
remainder appeared to have no more staining than nor-
mal breast. None of the three lobular carcinomas on the
slide showed any eEF1A2 overexpression. There was no
significant correlation between eEF1A2 expression level
and tumour grade or lymph node positivity (data not
shown). The tumours had all been previously assessed for
p53 status; there appeared to be an association between
overexpression of eEF1A2 and wild-type p53, but this was
not statistically significant. The tendency to association
may be a reflection of the significant association between
ER positivity and p53 negativity (p = 0.012) in these
tumour samples. Only four out of the 22 ER-negative
tumours showed staining beyond background levels and
none had strong staining. We found a significant associa-
tion between eEF1A2 overexpression (scored as moder-
ate/strong) and ER positivity (P = 0.016, Fisher's exact
test). We then went on to examine 16 tissue sections from
ER positive breast tumours obtained from patients at the
Western General Hospital. Of these, 13 showed moderate
or strong staining with the anti-eEF1A2 antibody. Overall
then, 40 out of 63 breast tumours (63%) examined by
immunohistochemistry showed significant overexpres-
sion of eEF1A2.
Discussion
We have shown that the putative oncogene eEF1A2 is
upregulated in a high proportion of breast tumours. This
upregulation is considerably more significant in ER-posi-
tive tumours. There is little or no detectable expression of
eEF1A2 in normal breast tissue. It is not yet known
whether this overexpression results from amplification of
the  EEF1A2  gene in all cases; in the study of ovarianBMC Cancer 2005, 5:113 http://www.biomedcentral.com/1471-2407/5/113
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tumours by Anand et al [6] at least one tumour showed
overexpression in the absence of gene amplification, sug-
gesting that there are other mechanisms by which the gene
can be upregulated. There is a strong association between
ER-positivity and eEF1A2 overexpression which is worthy
of further study.
There also appears to be a weak correlation between the
absence of p53 mutations and eEF1A2 overexpression. It
is possible that eEF1A2 is not upregulated in tumours
with p53 mutations because wild-type p53 is required for
expression of eEF1A2 in certain cell types; it has been
shown that p53 can upregulate expression of eEF1A1 [11],
and the p53 binding sites identified in the gene encoding
eEF1A1 are shared with that encoding eEF1A2 (unpub-
lished observations). On the other hand it is conceivable
that upregulation of eEF1A2 expression rather than p53
mutation is an alternative route for tumours to evade
apoptosis in certain cancers.
The basis for the oncogenicity of eEF1A2 is still unclear.
We, like Anand et al, have shown that the levels of eEF1A1
in tumours which over-express eEF1A2 are unchanged
(data not shown), suggesting that these tumours might
have a greater capacity for protein synthesis. However, it
has been known for many years that eEF1A is in excess
over the other components of the translation elongation
apparatus [12], so eEF1A is unlikely to be rate-limiting in
protein synthesis. eEF1A1 has been shown to determine
the susceptibility of a number of independent cell lines to
chemical- and UV-induced transformation [13] and has
been identified as an actin binding protein in rat breast
tumour cells, where it was found to be more highly
expressed in metastatic than non-metastatic cells [14]. It is
not yet clear whether these properties are shared with
eEF1A2, but the availability of specific antibodies that dis-
tinguish between the two isoforms should allow us to
shed light on this. One hypothesis is that the non-canon-
ical ("moonlighting") properties of eEF1A1 [15] and
eEF1A2 differ so that, for example, the way eEF1A2 inter-
acts with the cytoskeleton might differ from that of
eEF1A1 and affect the properties of cells which are
expressing high levels of both isoforms. It has been
shown, for example, that forced overexpression of eEF1A
affects the cytoskeleton in both S. pombe and S. cerevisiae
[16,17]. Alternatively, it has been shown that eEF1A1 and
eEF1A2 differ in terms of their response to apoptotic
agents [18]; the finding that eEF1A2 is anti-apoptotic, at
least in certain conditions, has obvious implications for
the possible role of eEF1A2 in tumourigenesis. The obser-
vation that eEF1A2 expression is seen in the majority of
cell lines, regardless of the tissue of origin, suggests that
Western blot analysis using an anti-eEF1A2 antibody on a range of cell lines Figure 1
Western blot analysis using an anti-eEF1A2 antibody on a range of cell lines. The loading control is GAPDH.
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eEF1A2 expression may be triggered by the general proc-
ess of transformation. This idea is strengthened by the fact
that most of the few cell lines which do not express
eEF1A2 tend to be untransformed, such as NIH3T3 cells
(Figure 1).
The presence of increased levels of eEF1A2 in breast
tumours may provide a useful new diagnostic marker.
Further, eEF1A2 may prove to be a feasible target for ther-
apeutic intervention. It has already been shown that
growth-factor mediated eEF1A1 expression can be
blocked with anti-EGF antibodies [19]; it would be of
interest to examine the response of eEF1A2 to similar anti-
bodies. Investigations into non-canonical functions of
eEF1A molecules may shed new light on mechanisms of
oncogenicity.
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Real-time RT-PCR analysis of RNA from breast tumours Figure 2
(A) Real-time RT-PCR analysis of RNA from breast tumours. Each block on the × axis represents a different tumour. The 
amount of eEF1A2 message is shown normalised to GAPDH and expressed relative to the level of expression in the normal 
breast RNA samples (=1). ER-negative tumours are shown in white, ER-positive tumours are shown in black. The difference in 
mean expression between ER-positive and ER-negative samples is 7.2 units (p = 0.0087), 95% Confidence Interval 2.0 to 12.4 
units. (B) Average standardised RNA levels in ER-negative and ER-positive breast tumours. This difference is significant (P = 
0.0087, t-test).
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Immunohistochemistry of eEF1A2 in the breast Figure 3
Immunohistochemistry of eEF1A2 in the breast. The panel labelled N shows the antibody staining weakly in a normal breast 
section. Panels T1 to T5 show breast tumours staining strongly with the anti-eEF1A2 antibody. Magnification ×10.
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